Investing in potentially the first cancer therapy to work in all tumours, irrespective of strain or mutation.
We will be undertaking a Series A in 2021 for funding GMP readiness and final pre-clinicals to get authorisation to run our first-in-human PoC trials in a range of solid tumours.
If you are an interested investment fund please email us.
Proudly Supported by / Partnered with:
Note: This website contains certain statements that are not historical facts and may be forward-looking statements, please see our legal notices.